JP2019521704A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521704A5
JP2019521704A5 JP2019516099A JP2019516099A JP2019521704A5 JP 2019521704 A5 JP2019521704 A5 JP 2019521704A5 JP 2019516099 A JP2019516099 A JP 2019516099A JP 2019516099 A JP2019516099 A JP 2019516099A JP 2019521704 A5 JP2019521704 A5 JP 2019521704A5
Authority
JP
Japan
Prior art keywords
seq
domain
nucleic acid
amino acid
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019516099A
Other languages
English (en)
Japanese (ja)
Other versions
JP7070932B2 (ja
JP2019521704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/036178 external-priority patent/WO2017214167A1/en
Publication of JP2019521704A publication Critical patent/JP2019521704A/ja
Publication of JP2019521704A5 publication Critical patent/JP2019521704A5/ja
Application granted granted Critical
Publication of JP7070932B2 publication Critical patent/JP7070932B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019516099A 2016-06-06 2017-06-06 Baff-r標的化キメラ抗原受容体修飾t細胞及びその使用 Active JP7070932B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346324P 2016-06-06 2016-06-06
US62/346,324 2016-06-06
US201662396767P 2016-09-19 2016-09-19
US62/396,767 2016-09-19
PCT/US2017/036178 WO2017214167A1 (en) 2016-06-06 2017-06-06 Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof

Publications (3)

Publication Number Publication Date
JP2019521704A JP2019521704A (ja) 2019-08-08
JP2019521704A5 true JP2019521704A5 (enExample) 2020-07-16
JP7070932B2 JP7070932B2 (ja) 2022-05-18

Family

ID=59071115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516099A Active JP7070932B2 (ja) 2016-06-06 2017-06-06 Baff-r標的化キメラ抗原受容体修飾t細胞及びその使用

Country Status (10)

Country Link
US (3) US11161908B2 (enExample)
EP (1) EP3464371A1 (enExample)
JP (1) JP7070932B2 (enExample)
KR (6) KR102356864B1 (enExample)
CN (2) CN115960251A (enExample)
AU (2) AU2017277269C1 (enExample)
CA (1) CA3026640A1 (enExample)
IL (4) IL308798A (enExample)
SG (1) SG11201810887UA (enExample)
WO (1) WO2017214167A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Car t細胞療法のための方法および組成物
CN115960251A (zh) 2016-06-06 2023-04-14 希望之城 Baff-r靶向嵌合抗原受体修饰的t细胞及其用途
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
US20200199232A1 (en) * 2018-12-19 2020-06-25 City Of Hope Baff-r bispecific t-cell engager antibody
WO2020172440A1 (en) * 2019-02-20 2020-08-27 Qin Hong Baff-r/cd19 targeted chimeric antigen receptor-modified t cells and use thereof
US12023354B2 (en) 2019-05-31 2024-07-02 Case Western Reserve University Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells
GB2607716B (en) * 2019-10-01 2024-10-30 Univ Case Western Reserve Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
CN111499723B (zh) * 2020-05-28 2021-04-09 广州百暨基因科技有限公司 一种嵌合抗原受体及其应用
US20250268939A1 (en) * 2021-05-19 2025-08-28 Shanghai Escugen Biotechnology Co., Ltd. Chimeric Antigen Receptor Molecule for Specifically Recognizing Baff-R and Application of Chimeric Antigen Receptor Molecule
CA3226798A1 (en) 2021-07-29 2023-02-02 James MATTHAEI Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases
EP4532534A1 (en) * 2022-06-01 2025-04-09 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Recombinant receptors binding b cell activation factor receptor and uses thereof
CN116143943B (zh) * 2022-10-31 2023-09-01 邦恩泰(山东)生物医药科技集团股份有限公司 一种靶向baffr嵌合抗原受体、car-t细胞及应用
WO2025006795A1 (en) * 2023-06-30 2025-01-02 Board Of Regents, The University Of Texas System Tsyn-seq: a t cell synapse-based tumor antigen identification platform
CN117050195B (zh) * 2023-10-13 2023-12-19 旭和(天津)医药科技有限公司 一种靶向baffr嵌合抗原受体、car-t细胞和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
AP2007004034A0 (en) * 2004-12-31 2007-06-30 Genentech Inc Polypeptides sthat bind br3 and uses thereof
CN106459924A (zh) 2014-04-23 2017-02-22 得克萨斯州大学系统董事会 用于疗法中的嵌合抗原受体(car)及其制备方法
GB201412658D0 (en) * 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
CN115960251A (zh) * 2016-06-06 2023-04-14 希望之城 Baff-r靶向嵌合抗原受体修饰的t细胞及其用途

Similar Documents

Publication Publication Date Title
JP2019521704A5 (enExample)
JP7390345B2 (ja) アゴニスト性tnf受容体結合物質
JP2020114264A5 (enExample)
JP2021177771A5 (enExample)
JP2018508215A5 (enExample)
JP2018508219A5 (enExample)
JP2019513394A5 (enExample)
JP2019511212A5 (enExample)
JP2019527557A5 (enExample)
JP2021087455A5 (enExample)
JP2020511136A5 (enExample)
RU2018105963A (ru) Антитело против глипикана-3 и его применение
JP2018029594A5 (enExample)
JP2015527366A5 (enExample)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2019527537A5 (enExample)
RU2018113510A (ru) Химерные рецепторы антигена, нацеленные на psca
JP2017513478A5 (enExample)
JP2019515646A5 (enExample)
JP2016514457A5 (enExample)
JP2019528769A5 (enExample)
JP2015513920A5 (enExample)
JP2018532407A5 (enExample)
JP2017519502A5 (enExample)
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe